Steed,
Thanks for posting this link. there's incredible exciting in the Neurology world
And this closing remark by Jeffrey L. Neul, MD, PhD (Annette Schaffer Eskind Chair and director of the Vanderbilt Kennedy Center, and professor of paediatrics at Vanderbilt University Medical Center, and the lead investigator on the phase 3 study of the drug, called LAVENDER (NCT04181723)).
[Paraphrased]
"I think it's exciting not only just for Rett syndrome but really for Neurodevelopmental disorders across the board and will give hope for people with other disorders..."
Media News, page-105
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.13 |
Change
0.020(0.15%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.44 | $13.07 | $5.021M | 378.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11501 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.18 | 1539 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |